Diarrhea
Conditions
Keywords
post-antibiotic diarrhea, intestinal microbiome
Brief summary
Chemotherapy is commonly used as myeloablative conditioning treatment to prepare patients for haematopoietic stem cell transplantation (HSCT). Chemotherapy leads to several side effects, with gastrointestinal (GI) mucositis being one of the most frequent. Current models of GI mucositis pathophysiology are generally silent on the role of the intestinal microbiome. The aim of the study is to identify functional mechanisms by which the intestinal microbiome may play a key role in the pathophysiology of GI mucositis, the investigators applied high throughput DNA-sequencing analysis to identify microbes and microbial functions that are modulated following chemotherapy.
Interventions
OTHERpatients stool collection
patients stool collection
Sponsors
Nantes University Hospital
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Participants with non-Hodgkin's lymphoma * Participants receiving the same myeloablative conditioning regimen for five consecutive days, including high-dose Carmustine (Bis-chloroethylnitrosourea), Etoposide, Aracytine and Melphalan.
Exclusion criteria
* Patients with a history of Inflammatory Bowel Diseases (IBD), exposed to probiotics, prebiotics or broad-spectrum antibiotics, or administered nasal-tube feeding or parenteral nutrition in the month prior to initiation of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| analyze of the fecal samples using 16S ribosomal ribonucleic acid (rRNA) gene sequencing | baseline |
Countries
France
Contacts
PRINCIPAL_INVESTIGATOREmmanuel Montassier, PH
Nantes Univetsity Hospital
Outcome results
None listed